Elite Pharmaceuticals, Inc. (ELTP) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Elite Pharmaceuticals, Inc. (ELTP) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. La acción obtiene una puntuación de 53/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 16 mar 2026Elite Pharmaceuticals, Inc. (ELTP) Resumen de Asistencia Médica y Tuberías
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets oral, controlled-release, and generic pharmaceuticals. Operating through ANDA and NDA segments, the company offers products for pain management, bariatrics, and cardiovascular diseases. Its focus on abuse-deterrent opioid formulations and contract manufacturing positions it within the competitive generic drug market.
Tesis de Inversión
Elite Pharmaceuticals, Inc. presents a compelling investment thesis based on its established position in the generic pharmaceuticals market and its strategic focus on developing abuse-deterrent opioid products. With a P/E ratio of 9.65 and a profit margin of 31.0%, the company demonstrates financial stability and profitability. Key value drivers include the continued demand for its generic products, such as Phentermine and Phendimetrazine, and the potential for revenue growth from its pipeline of abuse-deterrent formulations. Growth catalysts include successful clinical trials and regulatory approvals for its abuse-deterrent opioid products, as well as expansion of its contract manufacturing business. Potential risks include competition from other generic drug manufacturers, regulatory challenges, and the inherent uncertainties associated with pharmaceutical product development. Investors should closely monitor the company's progress in advancing its pipeline and securing new contract manufacturing agreements.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market Cap of $0.42B reflects the company's current valuation in the specialty pharmaceutical sector.
- P/E Ratio of 9.65 indicates the stock may be undervalued compared to its earnings.
- Profit Margin of 31.0% demonstrates strong profitability and efficient operations.
- Gross Margin of 51.1% highlights the company's ability to maintain healthy margins on its products.
- Beta of 0.36 suggests the stock is less volatile than the overall market.
Competidores y Pares
Fortalezas
- Established manufacturing capabilities for controlled-release and abuse-deterrent formulations.
- Portfolio of approved generic and branded products.
- Contract manufacturing agreements with third parties.
- Expertise in navigating the regulatory approval process.
Debilidades
- Limited financial resources compared to larger pharmaceutical companies.
- Dependence on a small number of key products.
- Exposure to pricing pressures in the generic drug market.
- Reliance on contract manufacturing agreements for a significant portion of revenue.
Catalizadores
- Upcoming: Potential FDA approval and launch of new abuse-deterrent opioid products.
- Ongoing: Expansion of contract manufacturing agreements with third parties.
- Ongoing: Continued revenue growth from existing generic and branded products.
Riesgos
- Potential: Competition from other generic drug manufacturers.
- Potential: Regulatory challenges and delays in product approvals.
- Potential: Pricing pressures and reimbursement changes.
- Potential: Product liability claims and litigation.
- Ongoing: Dependence on a small number of key products.
Oportunidades de crecimiento
- Expansion of Abuse-Deterrent Opioid Pipeline: Elite Pharmaceuticals is actively developing a range of abuse-deterrent opioid products. The market for these products is driven by the ongoing opioid crisis and the need for safer pain management options. Successful development and commercialization of these products could significantly increase revenue and market share. The global abuse-deterrent opioid market is projected to reach $3.9 billion by 2027, presenting a substantial growth opportunity for Elite. Timeline: Ongoing, with potential product launches within the next 3-5 years.
- Increased Contract Manufacturing Agreements: Elite Pharmaceuticals manufactures controlled-release products on a contract basis for third parties. Expanding this business segment can provide a stable revenue stream and leverage the company's manufacturing capabilities. The contract manufacturing market for pharmaceuticals is expected to grow as companies increasingly outsource production to specialized manufacturers. This represents a significant growth opportunity for Elite. Timeline: Ongoing, with potential for new agreements within the next 1-2 years.
- Geographic Expansion: Elite Pharmaceuticals currently focuses on the US market. Expanding into international markets, particularly emerging economies with growing healthcare needs, could drive revenue growth. This would require navigating regulatory hurdles and establishing distribution networks, but the potential rewards are significant. The global pharmaceutical market is expected to reach $1.57 trillion by 2028, offering ample opportunities for geographic expansion. Timeline: Medium-term, with potential entry into new markets within the next 3-5 years.
- Development of Novel Drug Delivery Systems: Investing in the development of novel drug delivery systems, such as extended-release or targeted delivery technologies, could provide a competitive advantage and create new revenue streams. These technologies can improve drug efficacy, reduce side effects, and enhance patient compliance. The market for advanced drug delivery systems is growing rapidly, driven by the demand for more effective and convenient treatments. Timeline: Long-term, with potential product launches within the next 5-7 years.
- Strategic Acquisitions: Elite Pharmaceuticals could pursue strategic acquisitions of complementary businesses or product lines to expand its portfolio and market reach. This could involve acquiring other generic drug manufacturers, specialty pharmaceutical companies, or drug delivery technology firms. Strategic acquisitions can accelerate growth and create synergies. The pharmaceutical industry is characterized by ongoing consolidation, presenting opportunities for strategic acquisitions. Timeline: Opportunistic, depending on market conditions and available targets.
Oportunidades
- Expansion of abuse-deterrent opioid pipeline.
- Increased contract manufacturing agreements.
- Geographic expansion into international markets.
- Development of novel drug delivery systems.
Amenazas
- Competition from other generic drug manufacturers.
- Regulatory challenges and delays in product approvals.
- Pricing pressures and reimbursement changes.
- Product liability claims and litigation.
Ventajas competitivas
- Specialized Manufacturing Capabilities: Elite possesses expertise in manufacturing controlled-release and abuse-deterrent formulations, creating a barrier to entry.
- Established Product Portfolio: The company has a portfolio of approved generic and branded products, providing a stable revenue base.
- Regulatory Expertise: Navigating the regulatory approval process for pharmaceuticals requires specialized knowledge and experience, which Elite possesses.
- Contract Manufacturing Relationships: Long-standing relationships with contract manufacturing partners provide a reliable source of revenue and diversification.
Acerca de ELTP
Elite Pharmaceuticals, Inc., incorporated in 1997 and headquartered in Northvale, New Jersey, is a specialty pharmaceutical company engaged in the development, manufacture, and commercialization of oral, controlled-release products, and generic pharmaceuticals. The company operates through two segments: Abbreviated New Drug Applications (ANDA) for Generic Products and New Drug Applications (NDA) for Branded Products. Elite Pharma owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals. Key products include Phentermine HCl tablets (Adipex-P brand) and Phendimetrazine Tartrate tablets (Bontril brand) for bariatrics, Naltrexone HCl tablets (Revia brand) for pain treatment, and Isradipine capsules for cardiovascular diseases. Elite also provides Oxycodone HCl immediate-release tablets (Roxycodone brand), Trimipramine Maleate immediate-release capsules (Surmontil brand), and Dextroamphetamine/Amphetamine tablets (Adderall brand). Additionally, Elite manufactures controlled-release products on a contract basis for third parties, focusing on pain, allergy, bariatric, and infection treatments. The company is actively developing abuse-deterrent opioid products, addressing a critical need in pain management. This diversified approach, combining generic pharmaceuticals with branded products and contract manufacturing, positions Elite Pharma within the competitive pharmaceutical landscape.
Qué hacen
- Develops and manufactures oral, controlled-release pharmaceuticals.
- Produces generic pharmaceuticals through Abbreviated New Drug Applications (ANDA).
- Develops branded products through New Drug Applications (NDA).
- Manufactures products for pain management, bariatrics, and cardiovascular diseases.
- Offers immediate-release and controlled-release formulations.
- Contract manufactures products for third parties.
- Develops abuse-deterrent opioid products.
Modelo de Negocio
- Develops and manufactures generic pharmaceuticals for various therapeutic areas.
- Generates revenue through the sale of its branded and generic products.
- Provides contract manufacturing services to other pharmaceutical companies.
- Focuses on developing and commercializing abuse-deterrent opioid formulations.
Contexto de la Industria
Elite Pharmaceuticals operates within the specialty and generic pharmaceutical industry, a sector characterized by intense competition and regulatory scrutiny. The market is driven by the increasing demand for affordable medications and the expiration of patents on branded drugs. Companies like Elite focus on developing and manufacturing generic versions of established drugs, as well as innovating in areas such as abuse-deterrent formulations. The industry faces challenges including pricing pressures, regulatory hurdles, and the need for continuous innovation to maintain competitiveness. The global generic drug market is projected to reach $459.07 billion by 2028, growing at a CAGR of 6.2% from 2021.
Clientes Clave
- Pharmacies and retail drug stores.
- Hospitals and healthcare providers.
- Wholesale distributors of pharmaceuticals.
- Other pharmaceutical companies through contract manufacturing agreements.
Finanzas
Gráfico e información
Precio de la acción de Elite Pharmaceuticals, Inc. (ELTP): Price data unavailable
Últimas noticias
-
Stocks That Hit 52-Week Highs On Tuesday
· 24 mar 2020
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para ELTP.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para ELTP.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de ELTP en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Nasrat Hakim
CEO
Nasrat Hakim serves as the CEO of Elite Pharmaceuticals, Inc. His background includes extensive experience in the pharmaceutical industry, with a focus on generic and specialty drug development and manufacturing. He has held various leadership positions in pharmaceutical companies, overseeing operations, research and development, and commercialization efforts. Hakim's expertise spans regulatory affairs, product development, and strategic planning within the pharmaceutical sector. His leadership is focused on driving innovation and growth at Elite Pharmaceuticals.
Historial: Under Nasrat Hakim's leadership, Elite Pharmaceuticals has focused on expanding its portfolio of generic and branded products, particularly in the area of abuse-deterrent opioid formulations. He has overseen the company's efforts to secure regulatory approvals for new products and expand its contract manufacturing business. Hakim has also emphasized operational efficiency and cost management to improve profitability. His strategic decisions have aimed to position Elite Pharmaceuticals for long-term growth and success in the competitive pharmaceutical market.
Información del mercado OTC de ELTP
The OTC Other tier represents the lowest tier of the OTC market, indicating that Elite Pharmaceuticals may not meet the minimum financial or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries higher risks due to the lack of regulatory oversight and transparency compared to companies listed on major exchanges like the NYSE or NASDAQ. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited regulatory oversight and disclosure requirements.
- Lower trading volume and liquidity compared to major exchanges.
- Potential for price manipulation and fraud.
- Greater risk of financial distress or bankruptcy.
- Limited access to company information and management.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's OTC Markets disclosure tier and compliance status.
- Check for any regulatory actions or legal proceedings against the company.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- The company has been in operation since 1997.
- Elite Pharmaceuticals has a portfolio of approved generic and branded products.
- The company has contract manufacturing agreements with third parties.
- They have a CEO with experience in the pharmaceutical industry.
Acciones de Elite Pharmaceuticals, Inc.: Preguntas Clave Respondidas
¿Cuáles son los factores clave para evaluar ELTP?
Elite Pharmaceuticals, Inc. (ELTP) actualmente tiene una puntuación IA de 53/100, indicando puntuación moderada. Fortaleza clave: Established manufacturing capabilities for controlled-release and abuse-deterrent formulations.. Riesgo principal a monitorear: Potential: Competition from other generic drug manufacturers.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de ELTP?
ELTP actualmente puntúa 53/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de ELTP?
Los precios de ELTP se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre ELTP?
La cobertura de analistas para ELTP incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en ELTP?
Las categorías de riesgo para ELTP incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Competition from other generic drug manufacturers.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de ELTP?
La relación P/E para ELTP compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está ELTP sobrevalorada o infravalorada?
Determinar si Elite Pharmaceuticals, Inc. (ELTP) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de ELTP?
Elite Pharmaceuticals, Inc. (ELTP) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available sources and may be subject to change.
- AI analysis is pending and may provide additional insights.